Literature DB >> 20174944

Nitinol biliary stent versus surgery for palliation of distal malignant biliary obstruction.

Rodrigo Castaño1, Tercio L Lopes, Oscar Alvarez, Victor Calvo, Leticia P Luz, Everson L A Artifon.   

Abstract

BACKGROUND: Curative resection of pancreatic and biliary malignancies is rare. Most tumors are inoperable at presentation, and palliation of jaundice often is the goal. Biliary decompression can be achieved by surgical diversion or endoscopic biliary stents. This study aimed to compare clinical outcomes between surgical bypass and endoscopic uncovered nitinol stents in the palliation of patients with malignant distal common bile duct obstruction.
METHODS: A multicenter, retrospective, cohort study investigated 86 patients with inoperable malignant distal common bile duct strictures at tertiary referral centers in Medellín, Colombia. These patients had undergone surgery (group 1) or placement of an uncovered 30-Fr self-expandable nitinol stent produced locally in Medellín, Colombia (group 2). The main outcome measurements included cumulative biliary patency, hospital stay, and patient survival.
RESULTS: The study enrolled 86 patients (mean age, 66 years; range, 43-78 years) including 40 patients in group 1 and 46 patients in group 2. Both groups were similar in terms of age, gender, liver metastasis, and diagnosis. Technical success was achieved for 38 patients in group 1 (95%) and 43 patients in group 2 (93%). Functional biliary decompression was obtained in for 35 of the surgical patients (88%) and 42 of the stented patients (91%). Group 2 had lower rates for procedure-related mortality (2 vs. 7.5%; p = 0.01), a lower frequency of early complications (8.7 vs. 45%; p = 0.02), and a shorter hospital stay (median, 6 vs. 12 days; p = 0.01). Recurrent jaundice occurred for three patients in group 1 (7.5%) and eight patients in group 2 (17.3%) (p = 0.198). Late gastric outlet obstruction occurred for 12.5% of the patients in group 1 and 13% of the patients in group 2 (p = 0.73). Despite the early benefits of stenting, no significant difference in the median overall survival between the two groups was found (group 1, 163 days; group 2, 178 days; p = 0.11). The limitations of this study included the small number of patients and the retrospective design.
CONCLUSIONS: Endoscopic stenting and surgery are effective palliation. The former is associated with fewer early complications and the latter with fewer late complications. Patients who do not qualify for curative resection may be better managed by stent placement. Surgery should be reserved for patients more likely to survive longer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20174944     DOI: 10.1007/s00464-010-0903-7

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  27 in total

1.  Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial.

Authors:  K D Lillemoe; J L Cameron; J M Hardacre; T A Sohn; P K Sauter; J Coleman; H A Pitt; C J Yeo
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

2.  Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice.

Authors:  J R Andersen; S M Sørensen; A Kruse; M Rokkjaer; P Matzen
Journal:  Gut       Date:  1989-08       Impact factor: 23.059

3.  Surgical bypass versus metallic stent for unresectable pancreatic cancer.

Authors:  D Maosheng; T Ohtsuka; J Ohuchida; K Inoue; K Yokohata; K Yamaguchi; K Chijiiwa; M Tanaka
Journal:  J Hepatobiliary Pancreat Surg       Date:  2001

4.  Wallstents versus plastic stents in malignant biliary obstruction: effects of stent patency of the first and second stent on patient compliance and survival.

Authors:  A Schmassmann; E von Gunten; J Knuchel; U Scheurer; H F Fehr; F Halter
Journal:  Am J Gastroenterol       Date:  1996-04       Impact factor: 10.864

5.  Surgical palliation for pancreatic cancer. The UCLA experience.

Authors:  S M Singh; W P Longmire; H A Reber
Journal:  Ann Surg       Date:  1990-08       Impact factor: 12.969

6.  A prospective randomised study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction.

Authors:  H Isayama; Y Komatsu; T Tsujino; N Sasahira; K Hirano; N Toda; Y Nakai; N Yamamoto; M Tada; H Yoshida; Y Shiratori; T Kawabe; M Omata
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

7.  Common bile duct obstruction due to malignancy: treatment with plastic versus metal stents.

Authors:  J Lammer; K A Hausegger; F Flückiger; F W Winkelbauer; R Wildling; G E Klein; S A Thurnher; L Havelec
Journal:  Radiology       Date:  1996-10       Impact factor: 11.105

8.  Endoscopic sphincterotomy before deployment of covered metal stent is associated with greater complication rate: a prospective randomized control trial.

Authors:  Everson L A Artifon; Paulo Sakai; Shinichi Ishioka; Sérgio B Marques; André S Lino; José E M Cunha; José Jukemura; Ivan Cecconello; Flair J Carrilho; Eduardo Opitz; Atul Kumar
Journal:  J Clin Gastroenterol       Date:  2008-08       Impact factor: 3.062

9.  Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction.

Authors:  P H Davids; A K Groen; E A Rauws; G N Tytgat; K Huibregtse
Journal:  Lancet       Date:  1992 Dec 19-26       Impact factor: 79.321

10.  A prospective, randomized, controlled trial of metal stents for malignant obstruction of the common bile duct.

Authors:  K Knyrim; H J Wagner; J Pausch; N Vakil
Journal:  Endoscopy       Date:  1993-03       Impact factor: 10.093

View more
  11 in total

1.  Efficacy of endoscopic self-expandable metal stent placement versus surgical bypass for inoperable pancreatic cancer-related malignant biliary obstruction: a propensity score-matched analysis.

Authors:  Ka Wing Ma; Albert Chi Yan Chan; Wong Hoi She; Kenneth Siu Ho Chok; Wing Chiu Dai; Simon Tsang; Tan To Cheung; Chung Mau Lo
Journal:  Surg Endosc       Date:  2017-08-04       Impact factor: 4.584

2.  Single-stage intraoperative transhepatic biliary stenting in patients with unresectable hepatobiliary pancreatic tumors.

Authors:  Yoshimi Iwasaki; Keiichi Kubota; Junji Kita; Masato Katoh; Mitsugi Shimoda; Tokihiko Sawada; Yukihiro Iso
Journal:  Surg Endosc       Date:  2012-07-18       Impact factor: 4.584

3.  Palliation of jaundice in pancreatic cancer: stent or surgery?

Authors:  H Ramesh
Journal:  Indian J Gastroenterol       Date:  2013-03-17

4.  Management of an occluded biliary metallic stent.

Authors:  Wiriyaporn Ridtitid; Rungsun Rerknimitr
Journal:  World J Gastrointest Endosc       Date:  2012-05-16

5.  Percutaneous transpapillary biliary stent placement for distal malignant biliary obstruction: Outcomes and survival analysis.

Authors:  Qing-Quan Zu; Jin-Xing Zhang; Bin Wang; Wei Ye; Sheng Liu; Hai-Bin Shi
Journal:  Turk J Gastroenterol       Date:  2019-08       Impact factor: 1.852

6.  Gastrointestinal stent update.

Authors:  Sung-Gwon Kang
Journal:  Gut Liver       Date:  2010-09-10       Impact factor: 4.519

7.  Comparison of outcomes among secondary covered metallic, uncovered metallic, and plastic biliary stents in treating occluded primary metallic stents in malignant distal biliary obstruction.

Authors:  Jae Hee Cho; Tae Joo Jeon; Jeong Youp Park; Hee Man Kim; Yoon Jae Kim; Seung Woo Park; Jae Bock Chung; Si Young Song; Seungmin Bang
Journal:  Surg Endosc       Date:  2010-07-03       Impact factor: 4.584

8.  Endoscopic ultrasound-guided choledochoduodenostomy with a lumen-apposing, self-expandable fully covered metal stent for palliative biliary drainage.

Authors:  Joshua Blake French; Adam Wesley Coe; Rishi Pawa
Journal:  Clin J Gastroenterol       Date:  2016-03-08

Review 9.  Recent Advances in Gastrointestinal Stent Development.

Authors:  Jin-Seok Park; Seok Jeong; Don Haeng Lee
Journal:  Clin Endosc       Date:  2015-05-29

10.  Current surgical aspects of palliative treatment for unresectable pancreatic cancer.

Authors:  Konstantinos Karapanos; Iakovos N Nomikos
Journal:  Cancers (Basel)       Date:  2011-02-11       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.